Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human TNF receptor II antibody fusion protein in active rheumatoid arthritis
CTR20171220Phase 3Completed
- Sponsor
- Shanghai Celgen Biopharma
- Start
- Nov 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of etanercept in rheumatoid arthritis (RA), sponsored by Shanghai Celgen Biopharma. Started Nov 2017; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20171220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171220.